NASDAQ: NDRAEndra Life Sciences Inc Stock
$4.94+0.00 (+0%)
Updated Dec 17, 2025
NDRA Price
$4.94
Fair Value Price
$2.36
Market Cap
$5.76M
52 Week Low
$2.90
52 Week High
$11.96
P/E
0.25x
P/B
33.62x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.01M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
10.46
Operating Cash Flow
-$5M
Beta
1.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NDRA Overview
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NDRA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
NDRA
Ranked#44 of 47
Ranked#44 of 47
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.81 | A | |
| $695.60 | B | |
| $562.56 | B |
Be the first to know about important NDRA news, forecast changes, insider trades & much more!
NDRA News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NDRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NDRA ($4.94) is overvalued by 109.63% relative to our estimate of its Fair Value price of $2.36 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NDRA ($4.94) is not significantly undervalued (109.63%) relative to our estimate of its Fair Value price of $2.36 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NDRA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more NDRA due diligence checks available for Premium users.
Valuation
NDRA fair value
Fair Value of NDRA stock based on Discounted Cash Flow (DCF)
Price
$4.94
Fair Value
$2.36
Overvalued by
109.63%
NDRA ($4.94) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NDRA ($4.94) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NDRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.25x
Industry
22.29x
Market
43.93x
NDRA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NDRA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
NDRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
33.62x
Industry
4.38x
NDRA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NDRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.6M
Profit Margin
0%
NDRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.0M
Liabilities
$1.8M
Debt to equity
10.46
NDRA's short-term assets ($1.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NDRA's short-term assets ($1.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NDRA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NDRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
$0.0
Financing
$149.5k
NDRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NDRA vs Diagnostic & Research Stocks
Endra Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.